Recruiting

Observational Study

Sponsor:

AbbVie

Code:

NCT07136467

Conditions

Non-Segmental Vitiligo (NSV)

Alopecia Areata

Hidradenitis Suppurativa

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.

Conditions

Non-Segmental Vitiligo (NSV)

Alopecia Areata

Hidradenitis Suppurativa

Study ID

NCT07136467

Start date

Sep 2, 2025

Status verified date

Feb, 2026

Completion date

Aug, 2027

Anticipated

Primary completion date

Aug, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)
  • Participants Ability to understand study questionnaires, with caregiver support as required for adolescents

Exclusion Criteria:

  • Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)
  • Unable or unwilling to comply with study requirements and PRO collection

Study Design

Enrollment

2795 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants with Vitiligo

Participants with vitiligo will undergo a single-visit data collection per routine clinical practice

Participants with Alopecia Areata

Participants with alopecia areata will undergo a single-visit data collection per routine clinical practice

Participants with Hidradenitis Suppurativa

Participants with hidradenitis suppurativa will undergo a single-visit data collection per routine clinical practice

Primary outcome measure

  • Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only [ Time Frame: Up to Day 1 ]
  • Measuring scalp hair loss, assessed by the Severity of Alopecia Tool (SALT) score. AA only [ Time Frame: Up to Day 1 ]
  • Measuring facial skin depigmentation, assessed by the Facial Vitiligo Area Scoring Index (F-VASI) Vitiligo Only [ Time Frame: Up to Day 1 ]
  • Vitiligo Quality of Life (QOL), assessed by Vitiligo Quality of Life Score (VitiQoL) Vitiligo Only [ Time Frame: Up to Day 1 ]
  • Hidradenitis Suppurativa (HS) Quality of Life (QOL), assessed by Dermatology Life Quality Index (DLQI)/Children's Dermatology Life Quality Index (CDLQI) HS only [ Time Frame: Up to Day 1 ]
  • Measuring disease severity, assessed by the International Hidradenitis Suppurativa Severity Scoring System (IHS4) HS only [ Time Frame: Up to Day 1 ]

Central Contacts and Locations

Central contacts

Beth Rycroft

844-663-3742beth.rycroft@abbvie.com

Locations

Dermatology Research Institute - Blackfoot Trail /ID# 276548

Recruiting

Calgary, Alberta, Canada, T2J 7E1

Rejuvenation Dermatology - Edmonton Downtown /ID# 276593

Recruiting

Edmonton, Alberta, Canada, T5J 3S9

Alberta Dermatology Consultants /ID# 277187

Recruiting

Edmonton, Alberta, Canada, T5N 1L5

Brunswick Dermatology Center /ID# 276546

Recruiting

Fredericton, New Brunswick, Canada, R3M 3Z4

Simcoderm Medical And Surgical Dermatology Centre /ID# 276838

Recruiting

Barrie, Ontario, Canada, L4M 7G1

DermEffects /ID# 276594

Recruiting

London, Ontario, Canada, N6H 5L5

Lynderm Research Inc /ID# 276595

Recruiting

Markham, Ontario, Canada, L3P 1X2

York Dermatology Clinic & Research Centre /ID# 276697

Recruiting

Richmond Hill, Ontario, Canada, L4C 9M7

Dermacentre Recherches /Id# 277593

Recruiting

Pointe-Claire, Quebec, Canada, H9R 5M7

More Information

Sponsor

AbbVie

Last update posted

Feb 13, 2026

Last verified

Feb, 2026

Keywords

  • Non-Segmental Vitiligo (NSV)
  • Alopecia Areata
  • Hidradenitis Suppurativa

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by AbbVie on 2026-02-13.